Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Post NSTEMI Invasive Strategy Timing

Post NSTEMI Invasive Strategy TimingThe aim of this meta-analysis, which included all randomized studies carried out to date, was to compare an early invasive strategy vs. a delayed invasive strategy in patients undergoing non ST elevation myocardial infarction (NSTEMI).

 

Even though there is no doubt invasive strategies reduce events rate such as death and re-infarction in NSTEMI patients, the adequate time for intervention remains controversial. Waiting too long may cause events (mainly repeat angina and infarction) and rushing may be associated to periprocedural events, because plaques are too unstable, since antiaggregation and anticoagulants have had not acted yet.

 

A previous meta-analysis on early invasive strategy vs. delayed invasive strategy had included 7 randomized studies; since then there have been 3 new studies, and the present work aims at updating the information with 10 randomized studies and 6,397 patients.

 

Mean time between randomization and PCI was between 30 minutes and 14 hours in the early invasive strategy group vs. 18.3 to 86 hours in the delayed invasive strategy group.

 

There were no differences in mortality primary end point (4% early invasive vs. 4.7% delayed; CI 95%: 0.67 to 1.09; p=0.20). Acute myocardial infarction rate was also similar (6.7% vs. 7.7%; CI 95%: 0.53 to 1.45; p=0.62).

 

The early invasive strategy was associated to a reduction of recurrent ischemia and refractory angina (3.8% vs. 5.8%; CI 95%: 0.40 to 0.74; p<0.01) and also to a shorter hospital stay (mean 112 hours vs. 168 hours; p<0.01).

 

Mayor bleeding was similar between both groups (3.9% vs. 4.2%; p=0.64).

 

Conclusion

An early invasive strategy does not reduce the risk of death or acute myocardial infarction compared to a delayed strategy. A reduction of hospital stay and refractory angina was observed.

 

Editorial Comment

The RIDDLE-NSTEMI, published by J Am Coll Cardiol Intv. 2016, randomized 323 patients undergoing non ST elevation myocardial infarction to immediate intervention (<2 hrs. after randomization) vs. delayed intervention (2 to 72 hrs. after randomization) observing, at 30 days, primary end point of death and repeat MI was less frequent in the immediate intervention group (4.3% vs. 13%; p= 0.008).

 

This study was the first to provide evidence in favor of hard points such as death or infarction, but based only on 323 included patients, several randomized studies and 2 meta-analysis (including the present one) with contradicting results that seem insufficient to change the daily practice.

 

Original Title: Timing of Coronary Invasive Strategy in Non–ST-Segment Elevation Acute Coronary Syndromes and Clinical Outcomes And Updated Meta-Analysis.

Reference: Laurent Bonello et al. J Am Coll Cardiol Intv. 2016;9(22):2267-2276.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...